Abstracts tagged "inflammatory arthritis and risk assessment"

Abstract Number: 415 • 2013 ACR/ARHP Annual Meeting
Stability Of Carotid Intima Media Thickness and No Plaque Formation In Inflammatory Arthritis Patients On Biologics Over One Year
Stephanie O. Keeling¹, Asvina Bissonauth², Jeff Odenbach², Quazi Ibrahim³ and Michael Sean McMurtry⁴, ¹Division of Rheumatology, Department of Medicine, University of Alberta, Canada, Edmonton, AB, Canada, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Medicine, EPICORE, Edmonton, AB, Canada, ⁴Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Carotid intima media (cIMT) measurement is a validated surrogate measure of cardiovascular (CV) disease. Our aim was to evaluate baseline and follow-up cIMTs in…
Abstract Number: 69 • 2012 ACR/ARHP Annual Meeting
The Presence of Asymptomatic Carotid Plaques in Patients with Inflammatory Joint Disease Results in Inadequate Treatment to Lipid Targets in Cardiovascular Disease Prevention
Anne G. Semb¹, Silvia Rollefstad², Inge C. Olsen³, Desiree van der Heijde⁴ and Tore K. Kvien⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The prevalence of asymptomatic carotid plaque (a-CP) is high in patients with inflammatory joint disease (IJD). Patients with a-CP should receive intensive lipid lowering…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].